Objectives Behind Patent Commercialization: A Strategic Outlook for Organizations

Not every organization that files a patent wants to sell a product. Some want to protect national security. Others want to give their technology away for free. And still others simply want a steady stream of royalty income. The objectives behind patent commercialization are far more varied than most people assume – and understanding them is key to grasping how intellectual property actually functions in the real world. Organizations across sectors – from government defence labs to NGOs to small businesses – approach patents with fundamentally different goals, shaped by their mission, resources, and the markets they operate in.

Why objectives matter in patent commercialization 🔗

Patent commercialization, at its core, means turning a patented invention into economic or social value – whether through licensing, outright sale, or market launch. But “value” means different things to different stakeholders. A defence research body and a biotech startup may both hold patents, yet their reasons for commercializing (or not commercializing) those patents can be entirely different. Mapping these objectives by organization type gives a clearer picture of how the patent system actually operates in practice.

It is also worth noting the scale of the challenge. In India, fewer than 5% of patents ever reach the market, a figure that mirrors global trends. This low commercialization rate is not purely a failure of innovation – it often reflects deliberate strategic choices made by the organizations holding those patents.

Strategic R&D institutions: safeguarding national interests 🔗

Government-backed strategic research organizations – such as those working in defence and space – occupy a unique position in the patent landscape. Their primary objective is not profit. It is sovereignty and self-reliance.

India’s Defence Research and Development Organisation (DRDO) is a clear example. With a network of over 50 national laboratories developing technologies ranging from missile systems to naval electronics, DRDO’s patenting activity is driven by national security imperatives. The organization files patents not to generate royalty income from the open market, but to retain control over sensitive technologies and ensure they cannot be freely replicated by foreign entities or competitors.

This approach is sometimes referred to as a defensive patent strategy – filing patents primarily to block others from claiming the same technology, rather than to commercially exploit it directly. In DRDO’s case, licenses for the use of DRDO patents are granted to Indian industries at zero license fees and zero royalty, a policy introduced to boost domestic defence manufacturing under the Make in India initiative. This means DRDO retains commercialization rights and control over sensitive IP while simultaneously making it accessible to Indian industry for strategic purposes.

The broader goal here is technological self-reliance – what India’s defence policy calls Atmanirbharta. DRDO had signed over 1,400 Transfer of Technology agreements with Indian firms to supply components to India’s defence setup, a model where patents serve as instruments of national capability-building rather than revenue generation.

Societal organizations and NGOs: patents for public good 🔗

At the other end of the spectrum sit societal organizations and non-governmental bodies whose objective is public benefit rather than profit. These organizations file or hold patents not to monetize them in the traditional sense, but to ensure that critical technologies remain accessible to those who need them most.

This model closely resembles the logic of open-source software. The intention is to make innovations available freely or at minimal cost, preventing others from restricting access to socially vital technologies by patenting them first. A well-cited global example is Nutriset, which developed Plumpy’Nut – a peanut-based paste used by NGOs to treat severe malnourishment – and eventually began licensing the patent to affiliates in the developing world, prioritizing humanitarian access over commercial returns.

The rationale for patenting in these cases is preventive: if an NGO or public-interest organization does not patent its innovation, a private commercial entity could potentially file a similar patent and then charge for access – effectively cutting off the communities the original technology was meant to serve. Holding the patent defensively ensures the technology remains in the public domain or under controlled, affordable access.

Large corporations: defensive patents and investment protection 🔗

For large corporations, patent commercialization is overwhelmingly strategic. Big companies – especially in sectors like pharmaceuticals, technology, and manufacturing – file substantial patent portfolios not always because they intend to manufacture every patented product, but because patents serve as competitive shields.

Defensive patenting by large corporations works on a simple principle: the more patents a company holds in a technological space, the harder it becomes for competitors to operate in that space without risking infringement. A large portfolio also provides leverage in cross-licensing negotiations – where two companies agree to allow each other access to their respective patents, often without any money changing hands.

This is especially evident in technology-intensive sectors. Global technology companies have expanded their R&D operations in India at scale, with the country hosting over 1,700 Global Capability Centers engaged in high-end engineering, semiconductor design, and product innovation. Patent filings by these corporations in India are not merely about the Indian market – they are about embedding India into global R&D architecture while simultaneously building IP fences around core innovations.

The primary commercial objective of large corporations is therefore twofold: protect existing investments in R&D, and deter potential infringers. Revenue from licensing is a secondary objective, though it can be substantial when a company’s patents cover foundational technologies.

Small and medium businesses: licensing as the primary route 🔗

Small and medium-sized businesses (SMBs) face a fundamentally different set of constraints. They typically lack the capital, manufacturing infrastructure, or distribution networks needed to commercialize a patented invention on their own. As a result, their primary objective when filing a patent is to license it – to allow larger entities to use the technology in exchange for royalties.

This is a commercially rational position. Licensing allows an SMB to generate revenue from its innovation without bearing the full cost and risk of bringing a product to market. Licensing is particularly preferred where patents are developed in an industry-academia collaboration environment or arise from business transactions such as joint ventures, making it a natural fit for smaller innovators who often work in partnership with academic or research institutions.

In India, this dynamic is supported by government schemes. The Department of Scientific and Industrial Research’s PACE scheme provides support to industries and institutions to take innovations from the laboratory stage to commercialization, specifically to bridge the gap that resource-constrained SMBs cannot cross on their own. Similarly, bodies like BIRAC offer IP and technology management services to SMEs and startups to facilitate patent filing and eventual commercialization.

For an SMB, the patent is essentially a negotiating instrument – it creates a legal entitlement that can be converted into a royalty stream, making a small company’s innovation commercially viable without requiring it to become a manufacturer.

R&D institutions and universities: licensing and joint ventures 🔗

Academic institutions and dedicated R&D labs occupy their own distinct category. Their objective when commercializing patents is typically to generate revenue that can be reinvested into further research, or to form structured commercial partnerships through joint ventures.

The Government of India has emphasized university-industry technology transfer as a mechanism for creating socially useful innovation. However, the gap between aspiration and practice remains significant. The same research notes that while awareness of patenting is reasonably high among Indian academia, the concept of commercializing inventions is not yet deeply embedded – with most IP and technology transfer cells focusing primarily on licensing (42%) and technology evaluation (49%), with marketing receiving far less attention.

The preferred commercialization route for universities and public R&D labs is the licensing arrangement – granting a company the right to use or manufacture a patented technology in exchange for royalties. Where greater involvement is warranted, institutions may pursue joint ventures, taking an equity stake or collaborative role in the commercial entity that brings the technology to market.

A notable example from India is the National Chemical Laboratory (NCL), a CSIR laboratory that has a decades-long history of commercializing technology both within India and abroad through industry collaboration – from launching organic chemicals in the 1950s to working with pharma companies on drug manufacturing processes after the 1970 Patents Act. This is the model that India’s academic institutions are now, with varying success, working to replicate.

The Indian academic sector has lagged behind counterparts in the US, Europe, China, and Japan on financial numbers from commercialization, largely due to a lack of strategic frameworks and resource allocation. Addressing this requires not just policy but structured institutional models that move beyond simply filing patents to actively managing the commercialization pipeline.

How objectives shape commercialization strategy 🔗

The objectives of different organizations ultimately determine which commercialization route they pursue. A strategic R&D body retains tight control and grants access selectively. A societal organization makes its patent freely available. A large corporation builds a portfolio to deter competitors. An SMB licenses its invention to survive and scale. A university seeks royalties or joint ventures to fund further research.

Understanding this diversity of objectives is important because it challenges the assumption that patent commercialization is always about maximizing profit. The commercialization of intellectual property rights has implications not just for individual organizations but for economic development and the balancing of social and commercial interests – particularly in a developing country context where equitable access to technology matters as much as the protection of innovation.

The patent system, in this sense, is a flexible instrument. Its value depends entirely on what the holder chooses to do with it – and that choice is always shaped by the organization’s underlying purpose.

What do you think? If a government-funded R&D institution develops a life-saving medical technology, should it be required to make the patent freely available, or does retaining commercialization rights serve a larger public interest? And as India’s universities work to close the gap with global counterparts on technology commercialization, what structural changes do you think are most critical to get there?

References

1. https://ipbulletin.in/patent-commercialization/
2. https://www.mondaq.com/india/patent/849260/commercializing-patents-methods-and-challenges
3. https://drdo.gov.in/drdo/
4. https://drdo.gov.in/drdo/ipr
5. https://www.rkdewan.com/articles/drdo-and-innovation-in-the-indian-defence-eco-system/
6. https://www.raconteur.net/legal/intellectual-property/open-source-sharing-patents-speed-innovation/
7. https://insights.greyb.com/resources/india-patent-trends-updated-2026/
8. https://ssrana.in/articles/patent-licensing-strategies-effective-ip-commercialization/
9. https://www.dsir.gov.in/patent-acquisition-and-collaborative-research-and-technology-development-pace
10. https://link.springer.com/article/10.1007/s13132-021-00747-4
11. https://www.scirp.org/journal/paperinformation?paperid=134627
12. https://www.nlunagpur.ac.in/PDF/Publications/CI-Dec-2023/5.Kanchankumar%20Tejram%20Shewale.pdf